Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma

NCT00091559 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00091559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00091559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2005
Completion date
March 13, 2006
Enrollment
74 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma, mycosis fungoides, sezary syndrome